Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lipoic acid (also known as alpha-lipoic acid, ALA) has been studied for its potential to reduce certain side effects of chemotherapy, particularly chemotherapy-induced peripheral neuropathy (CIPN). The rationale is based on its antioxidant properties, which may help mitigate oxidative stress and nerve damage caused by certain chemotherapeutic agents (such as platinum compounds and taxanes). Some preclinical studies suggest a potential neuroprotective effect, and a few small clinical trials have explored its efficacy in reducing neuropathy symptoms.

However, the evidence is mixed and generally limited by small sample sizes, short follow-up periods, and methodological weaknesses. Systematic reviews and meta-analyses as of 2024 indicate that while lipoic acid appears safe and well-tolerated, its benefits for mitigating chemotherapy side effects are modest at best. Some studies showed slight improvement in neuropathy symptoms, but others found no significant difference compared to placebo. As a result, major oncology guidelines do not recommend lipoic acid as a standard supportive care agent for chemotherapy-induced neuropathy or other side effects. There is currently insufficient high-quality evidence to support its widespread use in this context, but ongoing trials may clarify its role in the future.

In summary, while there is some scientific investigation into lipoic acid for chemotherapy side effects, the evidence is limited and not robust enough for strong clinical recommendations.

More about Lipoic Acid
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Lipoic Acid

Products containing Lipoic Acid